US FDA Grants Accelerated Approval To Etcamah For Advanced Breast Cancer With ESR1 Mutation
AZN•FDA grants accelerated approval
- US FDA grants accelerated approval to Etcamah for advanced breast cancer with ESR1 mutation.
- US FDA authorizes Guardant360 CDx assay as companion diagnostic for breast cancer.
Related News
Barclays: More oil is flowing out of Middle East than in earlier stages of the conflict, but market remains in a deficit, and inventory cushion is much smaller now
XLE•
PreAxia FY26 expenses more than doubled to $992,700; posts no revenue
PAXH•
